Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.

Autor: Dixon B; Department of Critical Care Medicine, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia. Electronic address: barry.dixon@svha.org.au., Smith RJ; Department of Critical Care Medicine, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia., Campbell DJ; Molecular Cardiology Research Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne and St Vincent's Hospital Melbourne, Melbourne, VIC, Australia., Moran JL; Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville, SA, Australia., Doig GS; Northern Clinical School Intensive Care Research Unit, University of Sydney, St Leonards, NSW, Australia., Rechnitzer T; Intensive Care Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia., MacIsaac CM; Intensive Care Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia., Simpson N; Intensive Care Unit, University Hospital Geelong, Geelong, VIC, Australia., van Haren FMP; Intensive Care Unit, The Canberra Hospital, Woden, ACT, Australia; Medical School, Australian National University, Canberra, ACT, Australia., Ghosh AN; Intensive Care Unit, Northern Hospital, Epping, VIC, Australia., Gupta S; Intensive Care Unit, Frankston Hospital, Frankston, VIC, Australia., Broadfield EJC; Intensive Care Unit, Bendigo Hospital, Bendigo, VIC, Australia., Crozier TME; Intensive Care Unit, Monash Medical Centre, Clayton, VIC, Australia., French C; Intensive Care Unit, Footscray and Sunshine Hospitals, Western Health, Sunshine, VIC, Australia., Santamaria JD; Department of Critical Care Medicine, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Apr; Vol. 9 (4), pp. 360-372. Date of Electronic Publication: 2021 Jan 22.